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Mercury is a toxic heavy metal which is widely dispersed in nature. Most human exposure results from ﬁsh consumption or dental
amalgam. Mercuryoccurs inseveral chemical forms,with complex pharmacokinetics. Mercury iscapable of inducing awide range
of clinical presentations. Diagnosis of mercury toxicity can be challenging but can be obtained with reasonable reliability. Eﬀective
therapies for clinical toxicity have been described.
1.Introduction
Mercury is a heavy metal of known toxicity, noted for in-
ducing public health disasters in Minamata Bay, Japan [1]
a n di nI r a q[ 2–4]. The clinical impact of smaller mercury ex-
posures remains controversial. It exists in several forms:
inorganic mercury, which includes metallic mercury and
mercury vapor (Hg0)a n dm e r c u r o u s( H g 2
++)o rm e r c u r i c
(Hg++) salts; and organic mercury, which includes com-
poundsinwhichmercuryisbondedtoastructurecontaining
carbon atoms (methyl, ethyl, phenyl, or similar groups). The
biological behavior, pharmacokinetics, and clinical signiﬁ-
cance of the various forms of mercury vary with chemical
structure. There is some interconversion in vivo between the
various forms of mercury. Inhaled elemental mercury vapor,
for example, is easily absorbed through mucus membranes
and the lung and rapidly oxidized to other forms (but not
so quickly as to prevent considerable deposition of elemental
mercury in the brain). Methyl mercury is easily absorbed
through the gut and deposits in many tissues, but does
not cross the blood-brain barrier as eﬃciently as elemental
mercury; however, on entering the brain it is progressively
demethylated to elemental mercury [5]. Mercury salts, in
contrast, tend to be insoluble, relatively stable, and poorly
absorbed.
Human toxicity varies with the form of mercury, the
dose and the rate of exposure. The target organ for inhaled
mercury vapor is primarily the brain [5]. Mercurous and
mercuric salts chieﬂy damage the gut lining and kidney [5],
while methyl mercury is widely distributed throughout the
body[5].Toxicityvarieswithdosage:largeacuteexposuresto
elemental mercury vapor induce severe pneumonitis, which
inextremecasescanbefatal[5].Low-gradechronicexposure
to elemental or other forms of mercury induces subtler sym-
ptoms and clinical ﬁndings, as discussed hereinafter.
There is considerable controversy about the clinical sig-
niﬁcance of exposure to the various forms of mercury and
some disagreement regarding techniques for clinical assess-
ment of mercury burden. This paper is intended to review
published data on these issues and to assess published
clinical experience using DMPS to remove mercury from the
human body. Most of the authors cited hereinafter consider
DMPS to be a stronger chelator than DMSA, with one ex-2 Journal of Environmental and Public Health
ception citing evidence that DMSA is more eﬀective at re-
moving organic mercury [6]. This is a complicated issue.
The absorption of DMPS and DMSA by ingestion is highly
variable from one patient to the next; DMPS can be given
intravenously, while DMSA cannot. DMPS is considerably
safer than penicillamine or British anti-Lewisite, as discussed
hereinafter. It is available for compounding in the United
States and is available over the counter in Germany.
2. Sources of Mercury Exposure
Most human exposure to mercury is caused by outgassing
of mercury from dental amalgam, ingestion of contaminated
ﬁsh, or occupational exposure, according to the World
Health Organization [7, 8].
Mercury exists in nature primarily as elemental mercury
or as a sulﬁde and is found in the earth’s crust at ap-
proximately 0.5 parts per million. Atmospheric exposures
occur from outgassing from rock or through volcanic activ-
ity. Human sources of atmospheric mercury include coal
burning [9] and mining (mercury and gold in particular).
Atmospheric elemental mercury settles in water, where it is
converted by microorganisms into organic (methyl or ethyl)
mercury, which is ingested by smaller creatures which are
eventually consumed by larger ﬁsh. Fish at the top of the
food chain (e.g., tuna, swordﬁsh, or shark) may concentrate
considerable mercury in their tissues.
Human mercury exposures occur chieﬂy [7, 8] through
inhalation of elemental mercury vapor via occupational or
dental amalgam exposure or through ingestion of mercury
bonded to organic moieties (methyl, dimethyl, or ethyl
mercury), primarily from seafood. Most human metallic
mercury exposure comes from mercury vapor outgassing
from amalgam ﬁllings, at a rate of 2 to 28 micrograms
per facet surface per day, of which about 80% is absorbed,
according to the World Health Organization [7, 8]a n d
Berglund et al. [10] .Al e s sc o m m o ns o u r c eo fm e r c u ryv a p o r
is spilled mercury [11], and there is a report in the literature
of Idiopathic Thrombocytopenic Purpura [12] caused by
vacuuming spilled mercury (thereby producing a major
acute exposure to mercury vapor).
Methyl and dimethyl mercury (organic mercury) usually
originate from biological sources, chieﬂy fresh or salt water
ﬁsh. Over three thousand lakes in the United States have
been closed to ﬁshing due to mercury contamination [5]a n d
many species of ocean ﬁsh are also tainted with considerable
concentrations of mercury [13].
3. Pharmacokinetics of MercuryExposure
3.1. Inorganic Mercury
3.1.1. Elemental or Metallic (Hg0)M e r c u r y .Approximately
80% of metallic mercury vapor outgassed from amalgams
is absorbed through inhalation [10, 14, 15], compared with
about 7 to 10% absorption of ingested metallic mercury
[5], and about 1% absorption of metallic mercury through
skin contact [5]. On entry to the body, mercury vapor has
great aﬃnity for sulfhydryl groups and bonds to sulfur-con-
taining amino acids throughout the body. Mercury vapor
is transported to the brain [16], either dissolved in serum
or adherent to red cell membranes. Metallic mercury passes
easily through the blood brain barrier [17] and through the
placenta,whereitlodgesinthefetalbrain[18].Metallicmer-
cury is, however, rapidly oxidized to mercuric mercury on
entry to the blood stream [5], although not so quickly as to
prevent considerable uptake by the central nervous system
while still in the metallic form.
In addition to the brain [16, 19–26], metallic mercury
is also deposited in the thyroid [5, 19, 21], breast [27],
myocardium [28, 29], muscles [5, 21], adrenals [5], liver
[5, 30–32], kidneys [5, 7, 8, 19, 20, 23, 30–32], skin [5, 7, 8],
sweat glands [5], pancreas [5], enterocytes [5, 30], lungs
[5, 23, 30], salivary glands [5], testes, and prostate [5]a n d
maybeassociatedwithdysfunctionofthoseorgans.Mercury
also has aﬃnity for binding sites on the surface of T cells and
for sulfhydryl groups inﬂuencing T cell function [33, 34].
Mercury deposits readily in placenta and fetal tissues and is
found in breast milk. [5, 18, 31, 35]
Metallic mercury is largely excreted as mercuric mercury
[5].Theexcretoryhalflivesofmetallicandmercuricmercury
vary widely, depending on the organ of deposition and redox
state, with values ranging from a few days to several months
[5], with some pools (e.g., CNS) having a half life exceeding
several years [5]. Hair mercury does not correlate with
brain content of metallic mercury [5]. These complexities
make accurate assessment of body burden challenging (see
Section 9 hereinafter).
3.1.2. Mercurous (Hg2
++)M e r c u r y .Mercurous mercury salt
in the form of Hg2Cl2 (calomel) is poorly soluble in water
and poorly absorbed by the intestine, although some portion
is thought to undergo oxidation to more readily absorbable
forms[36].Itisdoubtfulthatmercurousmercurysurvivesin
the body, other than as a transitional form between metallic
and mercuric mercury [5].
Some absorption evidently occurs, however, as calomel is
occasionally associated with pink disease, or acrodynia.
3.1.3. Mercuric (Hg++)M e r c u r y . Historically, mercuric chlo-
ride (HgCl2) was used as a preservative and for development
of photographic ﬁlm and was ingested accidentally or as a
suicide measure. It is a component of some skin-lightening
creams. Only about 2% of ingested mercuric chloride is
absorbed initially [37], although it is believed that its cor-
rosive eﬀect on the intestine may increase permeability and,
hence, absorption, with prolonged exposure [38]. Available
dataonskinpenetrationofmercuricmercuryareinsuﬃcient
to make quantitative comparison with ingestion or with
metallic mercury.
Like metallic mercury, mercuric mercury in the blood-
stream adheres to sulfhydryl groups on erythrocytes, metal-
lothionein, or glutathione or is suspended in plasma [26].
Mercuric mercury does not cross the blood-brain barrier
eﬃciently, but it does accumulate in quantity in the placenta,
fetaltissues,andamnioticﬂuid[35].Evidenceexistsshowing
transport of mercuric mercury via one or more amino acid
transporters [39], particularly that for cysteine, which mayJournal of Environmental and Public Health 3
account for accumulation in the brain [5]. Much of the body
burden of mercuric mercury resides in the proximal con-
voluted renal tubule [40] bonded to metallothionein [41].
Signiﬁcant deposition also occurs periportally in the liver
[42] and lesser amounts in epithelial tissues, choroidal plex-
us, and testes.
Excretion of mercuric mercury is largely through urine
and stool, although signiﬁcant amounts are shed through
sweat, tears, breast milk, and saliva [5, 43]. Half lives appear
to be multiphasic, as with metallic mercury, with human
studies suggesting an eﬀective half life of 42 days for 80%
of an oral tracer dose; the other 20% did not appear to
have a measureable rate of excretion [44]. This may reﬂect
demethylation to metallic mercury in the brain and other
organs or mechanisms yet to be determined.
3.2. Organic Mercury Compounds. Most available data on
organic mercury compounds refer to methyl mercury, which
is a major source of human mercury exposure, is found nat-
urally in ﬁsh, and is relatively stable. Ethyl mercury behaves
in a similar fashion to methyl mercury at the cellular level,
but with an excretory half life about one third as long [5].
Methyl mercury vapor is absorbed with similar (80%)
eﬃciency as metallic mercury vapor [5]. Intestinal absorp-
tion of methyl mercury from ﬁsh is also fairly eﬃcient, as
is absorption through the skin [5]. On entry to the blood-
stream, methyl mercury adheres to sulfhydryl groups, par-
ticularly to those in cysteine. Methyl mercury is deposited
throughout the body, with equilibrium between blood and
body occurring approximately four days after exposure [45].
Distribution to peripheral tissues seems to occur through
one or more transporters, especially the cysteine transporter,
probably adherent to the sulfhydryl group in cysteine [5].
Concentration of methyl mercury occurs in the brain,
liver, kidneys, placenta, and fetus, especially in the fetal
brain, as well as in peripheral nerves and bone marrow [5].
Deposited methyl mercury slowly undergoes demethylation
to inorganic mercury [46].
The excretory half life of methyl mercury in man is about
70 days, with approximately 90% being excreted in stool.
Some degree of enterohepatic circulation apparently occurs.
Perhaps 20% of methyl mercury is excreted in breast milk,
withtheactualamountvaryingwithseverityofexposure[5].
Hair mercury reﬂects blood methyl mercury at the time of
incorporation, but not elemental mercury [47], and hence is
not a good index of total body burden [5], given the short
half life of methyl mercury in blood.
Dimethyl mercury is also eﬃciently absorbed through
the skin, and there is a reported death of a scientist caused
by minimal skin contact [48].
4.Toxicity
4.1. Inorganic Mercury
4.1.1. Metallic Mercury Vapor. Mercury in all forms poisons
cellular function by altering the tertiary and quaternary
structure of proteins and by binding with sulfhydryl and
selenohydryl groups. Consequently, mercury can potentially
impair function of any organ, or any subcellular structure.
The chief target organ of mercury vapor is the brain, but per-
ipheral nerve function, renal function, immune function,
endocrineandmusclefunction,andseveraltypesofdermati-
t i sh a v eb e e nd e s c r i b e d[ 49].
With massive acute exposure to mercury vapor, erosive
bronchitis and bronchiolitis potentially leading to respira-
tory failure may be accompanied by CNS symptoms such as
tremor or erethism [50].
Chronic exposure to clinically signiﬁcant doses of mer-
cury vapor usually produces neurological dysfunction. At
low-level exposures, nonspeciﬁc symptoms like weakness,
fatigue, anorexia, weight loss, and gastrointestinal distur-
b a n c eh a v eb e e nd e s c r i b e d[ 51]. Higher exposure levels are
associated with mercurial tremor: ﬁne muscle fasciculations
punctuated every few minutes by coarse shaking. Erethism
may also be observed: severe behavior and personality chan-
ges, emotional excitability, loss of memory, insomnia, de-
pression, fatigue, and in severe cases delirium and hallu-
cination [10]. Gingivitis and copious salivation have been
described [5].
These symptoms may regress with cessation of exposure,
but in many cases do not. Persistent neurological symptoms
are common [52].
4.1.2. Mercurous Mercury. Calomel (Hg2Cl2)i ss t i l lu s e di n
some regions of the world as a laxative. Although poorly ab-
sorbed,someisconvertedtomercuricmercury,whichisabs-
orbed, and induces toxicity as expected with mercuric mer-
cury.
4.1.3.MercuricMercury. Acutepoisoningwithmercuricsalts
(typically HgCl2) generally targets the gastrointestinal tract
and the kidneys. Extensive precipitation of enterocyte pro-
teins occurs, with abdominal pain, vomiting, and bloody
diarrhea with potential necrosis of the gut mucosa. This
may produce death either from peritonitis or from septic or
hypovolemic shock. Surviving patients commonly develop
renal tubular necrosis with anuria [53].
Chronic poisoning with mercury salts is rare, usuallyalso
involving concomitant occupational exposure to mercury
vapor. Kidney toxicity involves either renal tubular necrosis
or autoimmune glomerulonephritis, or both [53]. Immune
dysfunctions include hypersensitivity reactions to mercury
exposure, including asthma and dermatitis, various types
of autoimmunity [54], and suppression of natural killer
cells [55] and disruption of various other lymphocyte sub-
populations [5].
Brain dysfunction is less evident than with other forms
of mercury. Thyroid dysfunction seems associated with inhi-
bition of the 5  deiodonases, with decreased free T3 and in-
creasedreverseT3[56].Accumulationinthetesticlesappears
to inhibit spermatogenesis [57]. Atrophy and capillary dam-
age have been described in thigh muscle [58].
4.2. Organic Mercury. M e t h y lm e r c u ryr e a c t swi t hs u l f h y d ry l
groupsthroughoutthebody,thereforepotentiallyinterfering
with the function of any cellular or subcellular structure.4 Journal of Environmental and Public Health
Mercury is believed to interfere with DNA transcription and
protein synthesis [59], including protein synthesis in the
developingbrain,withdestructionofendoplasmicreticulum
and disappearance of ribosomes [60]. Evidence suggests dis-
ruption of numerous subcellular elements in the central ner-
vous system and other organs and in mitochondria; adverse
eﬀects have also been described on heme synthesis [61],
cell membrane integrity in many locations [5], free radical
generation [27, 62, 63], neurotransmitter disruption, and
stimulation of neural excitoxins [5], resulting in damage to
many parts of the brain and peripheral nervous system [5].
Methyl mercury has been associated with reduction in
Natural Killer cell activity [64–67], as well as an imbalance
in Th2:Th1 ratios favoring autoimmunity [34, 68, 69].
Mercury is also possibly associated with disruption of DNA
repair [5, 27]. The aﬃnity of mercury for sulfhydryl groups
of the mitochondrial oxidative phosphorylation complex
[70] associated with destruction of mitochondrial mem-
branes may contribute to chronic fatigue syndrome.
5. ClinicalPresentation
5.1. Inorganic
5.1.1. Elemental (Metallic) Mercury. Acute exposure to a
largequantityofmercuryvaporinducespneumonitis, asdis-
cussed previously. Symptoms of low-grade chronic exposure
are more subtle and nonspeciﬁc: weakness, fatigue, anorexia,
weight loss, and gastrointestinal distress [5], sometimes re-
ferredtoasmicromercurialism[71].Athigherexposures,the
mercurial ﬁne tremor punctuated by coarse shaking occurs;
erethism, gingivitis, and excessive salivation have also been
described [5], as has immune dysfunction [34].
Objective ﬁndings include altered evoked potentials
and decreased peripheral nerve conduction velocity [72].
Objective measures of short-term memory may be inversely
correlated with urinary mercury in chloralkali workers [73].
Reduced color vision and visual acuity have also been ob-
served [74]. Changes in coordination, tremor, mental con-
centration capacity, facial expression, and emotional state
are also described [75], as are polyarthritis, various forms of
dermatitis, and a syndrome mimicking pheochromocytoma
[76].
Subtler clinical ﬁndings among dentists have been doc-
umented, including delayed reaction time, poor ﬁne motor
control, and deﬁcits in mental concentration, vocabulary,
task switching, and the One Hole test, as well as mood labil-
ity, all correlating with urinary mercury excretion [75]. Evi-
dence also links elemental mercury to depression, excessive
anger, and anxiety [77], as well as acute myocardial infarc-
tion, lipid peroxidation, and carotid atherosclerosis, in Fin-
land [78]; the Finnish experience may possibly be explained
by dietary selenium deﬁciency, since selenium antago-
nizes mercury toxicity. Other investigators, however, have
described associations between mercury and hypertension,
lipid peroxidation, ischemic heart disease, and stroke [79].
5.1.2. Mercuric Salts. Ingestion of mercuric chloride pro-
duces extensive precipitation of intestinal mucosal proteins,
mucosal necrosis, generalized abdominal pain, bloody diar-
rhea, and shock. If the patient survives, acute renal failure
may follow [5].
5.2. Organic Mercury. Methyl mercury and ethyl mercury
produce similar signs and symptoms. Most published data
r e f e rt om e t h y lm e r c u r y .S y m p t o m sr e l a t em o r et om a g n i -
tude of methyl mercury retention than to the rate of deposi-
tion. Acute exposures tend to have a latency period of one or
more weeks; once acquired, toxic doses are cleared slowly, if
at all [5].
Massive prenatal poisoning may induce a form of cere-
bralpalsy[5].Lesserprenataldoseshavebeenassociatedwith
neurodevelopmental delays and cognitive deﬁcits [80–82].
Postnatal exposures generate a range of symptoms rang-
ing from paresthesias, with lesser exposures, to ataxia, visual,
auditory, and extrapyramidal impairments with moderate
exposures and clonic seizures in more severe exposures, as
in Minamata [1]a n dI r a q[ 2–4].
Objective physical ﬁndings are similar to those seen with
elemental mercury exposure.
6. Laboratory Assessment of Mercury Exposure
Given the wide range of excretory half lives of the various
mercury pools, discussion of laboratory assessment will
combine the various forms into one discussion. It is im-
portant to recall that blood, hair, and urine mercury levels
reﬂect recent exposure and do not correlate with total body
burden [83–86]. Blood and urine levels correlate fairly well
to each other, but not to total body burden [87]. With half
life of all mercury pools in the blood estimated to be in the
rang eo fthr eet oﬁ v eda y s[88],during whicheither excretion
or deposition in solid organs occurs, more accurate means
of estimating body burden have been required.
That being said, the US federal biological exposure index
(BEI) is currently set at 50mcg/L urine. Aside from the
obvious problems associated with basing a monitoring index
on a measurement which only reﬂects current or recent ex-
posure, and not overall body burden, several clinical studies
show objective symptoms well below 50mcg/L, with many
proband values extending down into the low end of the re-
ference range for urinary mercury excretion [75, 89–94], ef-
fectively rendering the US federal BEI useless for clinical or
investigational purposes. Similar criticisms have been made
of the EPA Reference Dose for methylmercury [95]. As sum-
marized by Kazantzis, “it has not been possible to set a level
for mercury in blood or urine below which mercury related
symptoms will not occur” [96].
Because of these diﬃculties, provocation with a chelator
has been proposed as providing a more reliable esti-
mate of body burden, and DMPS (2,3 Dimercapto-1-Pro-
panesulfonate) has been found by a number of investigators
to provide a reliable estimate of body burden, safer than
British Anti-Lewisite and more potent than DMSA [75, 97–
101].Journal of Environmental and Public Health 5
7.DMPS:Safety
DMPS is an analog of British Anti-Lewisite (BAL) with
high aﬃnity for mercury. Due to its superior safety, it has
been widely used in Germany for the past ﬁfty years and is
available over the counter in that country. Protocols deter-
mining the pharmacokinetics of DMPS and evaluating its
use for diagnostic purposes have been published in Germany
[101], Sweden [102, 103], New Zealand [100], and Mexico
[104] and in the United States [105–109].
Maiorino et al. [106] gave his volunteers DMPS 300mg
orally; over 90% of the absorbed DMPS was converted
rapidly to disulﬁde forms. Published absorption of ingested
DMPS varies from 39% [107] to 60% [110]. The excretory
halflifeofunalteredDMPSwas4.4±1.1hours.Theexcretory
half life of the disulﬁde forms of DMPS was 9.9 ±1.6h o u r s .
Hurlbut et al.’s [107] volunteers were given an unusually
large dose of DMPS (3mg/kg intravenously over 5 minutes).
Twosubjectshadatransient20mmHgdropinsystolicblood
pressure during infusion, without other changes in vital
signs. Excretory half life of unaltered DMPS ranged from 1.3
to 4.0 hours. Half life of the altered DMPS was from 19.8 to
37.5 hours.
In each of the cited studies, mercury output following
provocation with DMPS correlated signiﬁcantly with amal-
gam number and/or occupational or dietary exposure. There
were no signiﬁcant complications in any of the trials. Con-
sequently, all the investigators but one [111] concluded that
urine output provoked by DMPS represented a fair estimate
of body burden.
8. DMPS: Efﬁcacy
Each of the test trials cited in the previous section and others
[112] showed statistically signiﬁcant increases in urinary
mercury output with administration of DMPS. With pro-
longed treatment, evidence of decreased body burden has
been inferred [113].
Several controlled clinical trials support this conclusion.
The largest was undertaken in the Phillippines in a gold min-
ing area [114]. Workers in gold mining who sustained on-
going exposure to elemental mercury were compared to
peoplelivingdownstreamwhoateﬁsh,whichcontainedcon-
siderablemethylmercury,andtocontrolswithoutsigniﬁcant
known mercury exposure. Probands from the two exposed
areas were chosen with elevated blood, urine and hair mer-
cury levels, and appropriate symptoms (tremor, sleepless-
ness,memoryloss,etc.)[115];controlshadnormallevelsand
were asymptomatic.
One hundred six probands completed the fourteen-day
trial with oral DMPS 400mg per day. The only complication
w a sa na l l e r g i cr a s hi no n ep a t i e n t ,w h ow a se x c l u d e df r o m
the trial. Blood mercury did not decrease during the trial,
despite increases in urine mercury up to 85-fold.
Despitetheshort(fourteen-day)durationofthetrial,sig-
niﬁcant improvements were observed in objective measures
like hypomimia, Romberg test, tests for tremor and ataxia,
pencil tapping, and Frostig visual perception. Most of the
patients reported subjective improvement in memory, sleep-
lessness, metallic taste, fatigue, anxiety, and paresthesias.
Treatment eﬃcacy was similar in the metallic mercury group
(miners) and in the methyl mercury group (downstream ﬁsh
eaters). Similar results were presented in a parallel study by
Drasch et al. [115].
A university case report from the United States of treat-
ment of occupational exposures to mercury vapor [116]
showed relief of muscle twitching, arthralgias, paresthesias,
night sweats, weight loss, and excessive salivation following
two weeks of oral DMPS 100mg TID followed by DMPS
100mg QID for an additional six weeks. Reduction of sym-
ptoms closely paralleled urine mercury output, which ta-
pered over time.
9. Discussion
Mercury toxicity is not often included in the diﬀerential dia-
gnosis of common subjective complaints such as fatigue,
anxiety, depression, odd paresthesias, weight loss, memory
loss,anddiﬃcultyconcentrating,butthesearethesymptoms
of low-grade chronic mercury exposure described by the in-
vestigators cited previously. Given the ability of the various
forms of mercury to deposit in most parts of the human
body, the range of symptoms potentially caused by mercury
is quite large.
Animal studies linking mercury toxicity to neurodegen-
erativediseases[117,118]raiseclinicalconcern,asdoaseries
of associations between mercury and neurodegenerative dis-
eases in humans [119–123].
Mercury exposure is not insigniﬁcant according to
WHO, as cited previously, and the NHANES reports suggest
widespread exposure in the United States, especially among
women [124, 125].
Diagnosis of mercury overload is diﬃcult. The com-
monly used modalities (blood, urine, and/or hair levels) do
not correlate with total body burden and oﬀer little diagnos-
tically useful information. Provocation with DMPS appears
to oﬀer a more accurate assessment of body burden.
Since provocation is safe and inexpensive, indications
for provocation must rest on clinical grounds: does the pa-
tient have multiple, vague symptoms similar to those de-
scribed in the mercury literature, without other plausible,
and potentially reversible, explanation? Is there a signiﬁcant
history of mercury exposure: multiple amalgam ﬁllings,
high seafood intake, and history of multiple thimerosal-con-
taining vaccinations or signiﬁcant occupational exposures?
Is there a family history of Alzheimer’s, Parkinson’s, or
other diseases with postulated links to mercury exposure? Is
there a history of known glutathione transferase (GST) poly-
morphisms, which decrease the body’s ability to clear heavy
metals like mercury?
If so, then provocation with a chelator may be indicated.
Published protocols [126–130]e x i s tw h i c hc a l lf o rp r o -
vocation with DMPS with or without EDTA, in sequence.
These are designed for safety, and for diagnostic breadth.
DMPS has far better aﬃnity for mercury than EDTA, but
EDTA is more eﬀective in removing lead, cadmium, nickel,
and other toxic metals. Provocation with both gives a fuller6 Journal of Environmental and Public Health
picture of overall metal burden. Patients with GST enzyme
abnormalities may also receive glutathione to expedite
excretion of chelated metal. For unknown reasons, patients
with GST polymorphisms tend to excrete mercury later in
their course of treatment than other heavy metals [131]; this
can sometimes produce early false negatives for mercury,
due to preferential excretion of lead and other metals. All
eﬀectivechelationprotocolscallforreplacementofbeneﬁcial
minerals, which are also removed by EDTA and DMPS.
There are currently no consensus criteria for the diagno-
sis of mercury overload, nor for overload of other toxic met-
als. Clinicians who specialize in this area generally consider
a provoked urine metal output more than 2 standard devia-
tions above the NHANES reference range a positive result.
Further research is required to clarify the relation be-
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